← Back to Search

Other

Nicotine Transdermal Patch for Peripheral Neuropathy

Phase 2
Waitlist Available
Led By Zhi-Jian Chen, MD, PhD
Research Sponsored by Virginia Commonwealth University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 79 days
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if a nicotine patch can help reduce nerve pain in cancer patients who have nerve damage from chemotherapy. The patch releases nicotine through the skin, which may help ease the pain.

Eligible Conditions
  • Peripheral Neuropathy
  • Nerve pain
  • Nerve Damage
  • Neuropathy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~79 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 79 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Efficacy of Short-term Nicotine Transdermal Patch Administration in the Treatment of Cancer Induced Peripheral Neuropathy (CIPN)
Secondary study objectives
Efficacy of Pain-related Changes and Degree of Functional Interference in the Treatment of CIPN
Number of Participants at Risk and Affected by Adverse Events (AEs) Related to the Transdermal Nicotine Patch.

Side effects data

From 2016 Phase 4 trial • 36 Patients • NCT02681510
75%
Insomnia
72%
Vivid Dreams
64%
Nausea
42%
Mood Changes
39%
Dizziness
19%
Skin Rash
19%
Sweating
14%
Shortness of Breath
14%
Vomiting
11%
Chest Tightness
3%
Angina
100%
80%
60%
40%
20%
0%
Study treatment Arm
Three Drug Intervention

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Nicotine Transdermal Patch AdministrationExperimental Treatment1 Intervention
Each patient will complete two 14-day treatment conditions, for 7 mg nicotine transdermal patch administration with a washout period in between (≥ 14 days and up to 21 days), then 14 mg nicotine transdermal patch administration (14 days).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nicotine Transdermal Patch
2016
Completed Phase 4
~190

Find a Location

Who is running the clinical trial?

Virginia Commonwealth UniversityLead Sponsor
716 Previous Clinical Trials
22,888,494 Total Patients Enrolled
2 Trials studying Peripheral Neuropathy
57 Patients Enrolled for Peripheral Neuropathy
Zhi-Jian Chen, MD, PhDPrincipal InvestigatorMassey Cancer Center
Renato Martins, MDPrincipal InvestigatorMassey Cancer Center
~1 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top